These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24354237)

  • 1. [From apixaban to aspirin in the prevention of recurrent venous thromboembolism].
    Diez-Ewald M
    Invest Clin; 2013 Sep; 54(3):231-3. PubMed ID: 24354237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of apixaban for venous and arterial thromboembolic disease.
    Prom R; Spinler SA
    Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts for the prevention of venous thromboembolism.
    Bramlage P; Pittrow D; Kirch W
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():4-11. PubMed ID: 15701142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism.
    Browne C; Lanitis T; Hamilton M; Li X; Horbyluk R; Mardekian J; Kongnakorn T; Cohen A
    J Med Econ; 2017 Jan; 20(1):98-106. PubMed ID: 27822962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J; Sullivan B; Khalabuda M; McBride BF
    J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
    Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
    Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulant therapy: basic principles, classic approaches and recent developments.
    Sinauridze EI; Panteleev MA; Ataullakhanov FI
    Blood Coagul Fibrinolysis; 2012 Sep; 23(6):482-93. PubMed ID: 22732252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of thrombosis in pregnancy: role of low-molecular-weight heparin.
    Kher A; Bauersachs R; Nielsen JD
    Thromb Haemost; 2007 Apr; 97(4):505-13. PubMed ID: 17393011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
    Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
    Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of venous thrombosis in cancer patients: practical aspects].
    Laza-Achille M; Desruennes E; Di Palma M
    Bull Cancer; 2006 Mar; 93(3):271-81. PubMed ID: 16567314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of venous thromboembolism in surgery, in laparoscopic surgery, in venous surgery and in urology].
    Gumulec J; Penka M; Bezdĕk R; Czudek S; Stursa M; Wróbel M; Brejcha M; Klodová D; Sumná E; Králová S
    Vnitr Lek; 2006 Mar; 52 Suppl 1():41-50. PubMed ID: 16637449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.
    Elías I; Oyagüez I; Alvarez-Sala LA; García-Bragado F; Navarro A; González P; De Andrés-Nogales F; Soto J
    Farm Hosp; 2016 May; 40(3):187-208. PubMed ID: 27145388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery.
    Bergqvist D
    Br J Surg; 2004 Aug; 91(8):965-74. PubMed ID: 15286956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Novel anticoagulants for stroke prevention in atrial fibrillation].
    Baumhäkel M; Schirmer SH; Böhm M
    Dtsch Med Wochenschr; 2010 Nov; 135(46):2304-8. PubMed ID: 21064013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.